CA2740434C - Compositions probiotiques et procedes pour induire et maintenir une perte de poids - Google Patents

Compositions probiotiques et procedes pour induire et maintenir une perte de poids Download PDF

Info

Publication number
CA2740434C
CA2740434C CA2740434A CA2740434A CA2740434C CA 2740434 C CA2740434 C CA 2740434C CA 2740434 A CA2740434 A CA 2740434A CA 2740434 A CA2740434 A CA 2740434A CA 2740434 C CA2740434 C CA 2740434C
Authority
CA
Canada
Prior art keywords
bacteria
probiotic composition
weight loss
subject
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2740434A
Other languages
English (en)
Other versions
CA2740434A1 (fr
Inventor
Brenda E. Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40227969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2740434(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2740434A1 publication Critical patent/CA2740434A1/fr
Application granted granted Critical
Publication of CA2740434C publication Critical patent/CA2740434C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition probiotique servant à induire ou à maintenir une perte de poids chez un sujet, la composition probiotique comprenant une quantité efficace d'une bactérie sélectionnée dans le genre Bacteroides et un vecteur pour administrer la bactérie au sujet.
CA2740434A 2007-10-26 2008-10-21 Compositions probiotiques et procedes pour induire et maintenir une perte de poids Active CA2740434C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98284407P 2007-10-26 2007-10-26
US60/982,844 2007-10-26
PCT/US2008/080601 WO2009055362A1 (fr) 2007-10-26 2008-10-21 Compositions probiotiques et procédés pour induire et maintenir une perte de poids

Publications (2)

Publication Number Publication Date
CA2740434A1 CA2740434A1 (fr) 2009-04-30
CA2740434C true CA2740434C (fr) 2017-11-07

Family

ID=40227969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2740434A Active CA2740434C (fr) 2007-10-26 2008-10-21 Compositions probiotiques et procedes pour induire et maintenir une perte de poids

Country Status (10)

Country Link
US (2) US9371510B2 (fr)
EP (1) EP2211879B1 (fr)
JP (1) JP2011500821A (fr)
CN (1) CN101903032A (fr)
AU (1) AU2008317000B2 (fr)
CA (1) CA2740434C (fr)
DK (1) DK2211879T3 (fr)
ES (1) ES2473625T3 (fr)
NZ (1) NZ585210A (fr)
WO (1) WO2009055362A1 (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2740434C (fr) * 2007-10-26 2017-11-07 Brenda E. Moore Compositions probiotiques et procedes pour induire et maintenir une perte de poids
PT3564357T (pt) 2010-02-01 2022-06-14 Rebiotix Inc Bacterioterapia para colite por clostridium difficile
CN102947441A (zh) * 2010-06-01 2013-02-27 穆尔研究企业有限责任公司 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法
HK1253538A1 (zh) * 2010-08-04 2019-06-21 Borody Thomas J 用於糞便菌群植入的組合物及其製備和使用方法
NZ618935A (en) 2010-08-04 2014-03-28 Karma Medical Prod Co Ltd Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CA2813606C (fr) 2010-10-07 2019-01-22 Sarkis K. Mazmanian Therapies aux probiotiques contre l'autisme
CN101982180A (zh) * 2010-11-01 2011-03-02 西藏贝珠雅药业有限公司 一种新型的益生菌活菌阴道栓体
ES2636439T3 (es) 2011-03-09 2017-10-05 Regents Of The University Of Minnesota Composiciones y métodos para el trasplante de microbiota de colon
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
CA2848762C (fr) * 2011-09-14 2021-07-27 Queen's University At Kingston Procede de traitement de troubles de l'appareil gastro-intestinal
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013176774A1 (fr) 2012-05-25 2013-11-28 Arizona Board Of Regents Marqueurs de microbiome et thérapies pour troubles du spectre autistique
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
WO2014036182A2 (fr) 2012-08-29 2014-03-06 California Institute Of Technology Diagnostic et traitement du trouble du spectre autistique
EP2945566A4 (fr) * 2013-01-15 2016-10-26 Metamodix Inc Système et procédé pour modifier la flore microbienne intestinale
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP2017512500A (ja) * 2014-03-25 2017-05-25 ギンゴー バイオワークス， インコーポレイテッド 細胞工学のための方法および遺伝システム
US20170252381A1 (en) * 2014-09-30 2017-09-07 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases
CN104546935A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN107208037A (zh) * 2014-09-30 2017-09-26 深圳华大基因科技有限公司 拟杆菌属在预防和治疗冠状动脉疾病中的用途
EP3012270A1 (fr) * 2014-10-23 2016-04-27 Institut Gustave Roussy Produits pour moduler la composition microbienne afin d'améliorer l'efficacité d'un traitement du cancer avec un bloqueur de vérification immunitaire
IL251844B2 (en) * 2014-10-23 2024-04-01 Roussy Inst Gustave Methods and products for modulation of microbiota composition to improve the effectiveness of cancer treatment with immune checkpoint blockade
EP3212207A4 (fr) 2014-10-30 2018-06-13 California Institute of Technology Compositions et procédés comprenant des bactéries pour l'amélioration du comportement dans les troubles neurodéveloppementaux
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
ES2794125T3 (es) * 2014-12-08 2020-11-17 Gi Biome Composición farmacéutica para prevenir o tratar enfermedades metabólicas, que comprende Bacteroides acidifaciens como principio activo
DK3065748T3 (da) * 2014-12-23 2018-01-29 4D Pharma Res Ltd En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation
NO3193901T3 (fr) 2014-12-23 2018-09-01
WO2016183577A1 (fr) 2015-05-14 2016-11-17 Crestovo Llc Compositions permettant la transplantation de flore fécale et méthodes de préparation et d'utilisation de ces dernières, et dispositifs pour leur administration
DK3297644T3 (da) 2015-05-22 2022-04-11 Univ Arizona State Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
ES2889902T3 (es) * 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
SI3650033T1 (sl) 2015-06-15 2022-05-31 4D Pharma Research Limited Sestavki, ki obsegajo bakterijske seve
EP3636272A1 (fr) 2015-06-15 2020-04-15 4D Pharma Research Limited Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TW202222339A (zh) 2015-06-15 2022-06-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
CN106389478B (zh) * 2015-07-31 2019-12-24 广州知易生物科技有限公司 脆弱拟杆菌在治疗和/或预防肥胖症或糖尿病中的应用
CN105106243A (zh) * 2015-08-03 2015-12-02 上海交通大学医学院附属瑞金医院 Bacteroides thetaiotaomicron VPI-5482在制备治疗或预防肥胖症药物中的应用
CN105030842A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Bacteroides intestinalis DSM 17393菌株的应用
MX2018006240A (es) 2015-11-20 2018-08-01 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN106852938A (zh) * 2015-12-09 2017-06-16 深圳华大基因研究院 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
CN105455084A (zh) * 2015-12-12 2016-04-06 关岭自治县白刺花养蜂农民专业合作社 一种白刺花蜂蜜的制备方法
US9622897B1 (en) 2016-03-03 2017-04-18 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SI3313423T1 (sl) 2016-03-04 2019-07-31 4D Pharma Plc Sestavki, ki vsebujejo bakterijske seve Blautia za zdravljenje visceralne preobčutljivosti
CN109642904A (zh) 2016-05-23 2019-04-16 加州理工学院 调节肠微生物群来治疗神经退行性病症
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (fr) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions et méthodes pour traiter la sclérose en plaques et des troubles associés
WO2018071536A1 (fr) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions et procédés pour traiter la cholangite sclérosante primitive et des troubles associés
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018187464A1 (fr) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions et méthodes pour traiter la diverticulite et des troubles associés
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
EP3624782A4 (fr) 2017-05-15 2021-05-05 Axial Biotherapeutics, Inc. Inhibiteurs d'amyloïde induite par voie microbienne
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2018218159A1 (fr) 2017-05-26 2018-11-29 Crestovo Holdings Llc Compositions lyophilisées comprenant des agents thérapeutiques à base de microbes fécaux et leurs procédés de fabrication et d'utilisation
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
EP4104843A1 (fr) 2017-06-14 2022-12-21 4D Pharma Research Limited Compositions comprenant des souches bactériennes
CN109223833A (zh) * 2017-07-10 2019-01-18 上海立龙生物科技有限公司 一种预防和改善肥胖的益生菌组合物
EP3664823B1 (fr) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition pour la prévention ou le traitement d'une infection entérococcique de la circulation sanguine
WO2019118984A2 (fr) 2017-12-15 2019-06-20 Solarea Bio, Inc. Compositions microbiennes et méthodes de traitement du diabète de type 2, de l'obésité et du syndrome métabolique
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11559479B2 (en) 2018-07-16 2023-01-24 ProBiora Health, LLC Beverage additive
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (fr) 2018-09-05 2022-07-06 Solarea Bio, Inc. Méthodes et compositions pour le traitement de maladie musculo-squelettiques
WO2020054728A1 (fr) * 2018-09-10 2020-03-19 国立研究開発法人理化学研究所 Composition pour inhiber l'activité de la trypsine, contenant, en tant que principe actif, une bactérie appartenant au genre paraprevotella
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
CN111714522B (zh) * 2019-03-04 2022-07-15 中国科学院微生物研究所 拟杆菌及其应用
GB201907782D0 (en) * 2019-05-31 2019-07-17 Mars Inc Method
ES2886646B2 (es) * 2020-06-17 2022-06-22 Consejo Superior Investigacion Cepa del genero bacteroides para su uso en el tratamiento y/o prevencion de trastornos alimentarios
CA3238788A1 (fr) 2021-11-22 2023-05-25 Eric Michael Schott Methodes et compositions pour le traitement de maladies musculo-squelettiques, le traitement d'une inflammation et la prise en charge de symptomes de la menopause

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5557520A (en) * 1978-10-26 1980-04-28 Nisshin Flour Milling Co Ltd Preparation of carcinostatic substance
ATE165738T1 (de) 1988-08-02 1998-05-15 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
AUPP816899A0 (en) * 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
JP2001346577A (ja) * 2000-06-07 2001-12-18 Katsunari Onishi ヒトラクトフェリン発現プラスミド及びこれを保有するバクテロイデス属形質転換細胞
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20040115177A1 (en) * 2001-10-12 2004-06-17 Harris Delbert L. Probiotic compositions and methods against bacterial infection in livestock animals
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
WO2005060937A1 (fr) 2003-12-23 2005-07-07 Chr. Hansen A/S Tablettes comprimees comprenant des micro-organismes probiotiques viables
GB0501540D0 (en) * 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
US20100233312A9 (en) * 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
US20100172874A1 (en) 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
CA2740434C (fr) * 2007-10-26 2017-11-07 Brenda E. Moore Compositions probiotiques et procedes pour induire et maintenir une perte de poids

Also Published As

Publication number Publication date
AU2008317000B2 (en) 2014-10-23
US10226490B2 (en) 2019-03-12
CN101903032A (zh) 2010-12-01
US9371510B2 (en) 2016-06-21
US20160310545A1 (en) 2016-10-27
AU2008317000A1 (en) 2009-04-30
EP2211879A1 (fr) 2010-08-04
WO2009055362A1 (fr) 2009-04-30
JP2011500821A (ja) 2011-01-06
ES2473625T3 (es) 2014-07-07
NZ585210A (en) 2012-07-27
CA2740434A1 (fr) 2009-04-30
DK2211879T3 (da) 2014-07-21
EP2211879B1 (fr) 2014-05-07
US20090110664A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
US10226490B2 (en) Probiotic compositions and methods for inducing and supporting weight loss
RU2346036C2 (ru) Пробиотики для нервно-мышечной функции кишечника
RU2567660C2 (ru) Bifidobacterium longum ATCC BAA-999 (BL999) И КОНТРОЛИРОВАНИЕ ВЕСА
KR102303587B1 (ko) 건선의 치료 및/또는 예방에서의 프로바이오틱스의 용도
JP2009511469A (ja) 脂肪代謝及び肥満に影響を及ぼすプロバイオティクス
CN109414464A (zh) 用于改善肠道健康的短暂共生微生物
CN109069549A (zh) 用于断奶的食物组合物
CN109451727A (zh) 益生菌和消化酶的组合物及其制备和使用方法
WO2007140621A1 (fr) Compositions probiotiques et leurs utilisations
CA2690058A1 (fr) Compositions probiotiques derivees de produits laitiers et leurs utilisations
CN102935092A (zh) 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用
US20170252381A1 (en) Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases
AU2019241546A1 (en) Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition
JP2007518463A (ja) 乾燥した生物学的治療用組成物、その使用、及びその投与のための装置及び方法
JP2013538827A (ja) 腎機能を増強させるための組成物および方法
JP6261688B2 (ja) Ｑｏｌ改善又は持続剤
JPH059124A (ja) インターロイキン産生能を調節するための組成物
JP2005532294A (ja) 腎機能を増強するための組成物及び方法
CN115651854A (zh) 一种植物乳杆菌yg06菌株及其应用
WO2021111980A1 (fr) Agent prophylactique ou d'atténuation de l'hypotension orthostatique, et composition contenant celui-ci
CN110384719B (zh) 可改善高血压的罗伊氏乳杆菌菌株gmnl-263及其组合物
TWM537906U (zh) 複合物微粒結構
TW202335676A (zh) 腸管免疫賦活劑及IgA產生促進劑
CN113730546A (zh) 一种治疗帕金森病的药物组合物及其用途
CN116019841A (zh) 治疗自闭症谱系障碍的方法和包含肠道菌群的多层滴丸

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130927